A Rapid Metabolomic Test for Early Diagnosis of Myocardial Infarction
|
By LabMedica International staff writers Posted on 03 May 2021 |

Image: A myocardial infarction (MI), commonly known as a heart attack, occurs when blood flow decreases or stops to a part of the heart, causing damage to the heart muscle (Photo courtesy of Wikimedia Commons)
A metabolomic platform with GC/MS (gas chromatography–mass spectrometry) and LC/MS (liquid chromatography–mass spectrometry) instrumentation has been developed to profile plasma metabolites of patients with chest pain for early detection of myocardial infarction (MI).
Investigators at Nanjing Medical University (People’s Republic of China) were working to develop a simple blood test to aid clinicians in diagnosing a heart attack with a rapid, noninvasive assay method.
To this end, they analyzed plasma metabolites in MI and non-MI chest pain cases to identify markers for diagnosis of MI based on metabolomics. Non-MI cardiac chest pain cases included unstable angina (UA), myocarditis, and valvular heart diseases. A total of 230 volunteers were recruited, consisting of 146 chest pain patients admitted with suspected MI (85 MIs and 61 non-MI chest pain cases) and 84 control individuals. Blood samples from all suspected MI cases were collected not longer than six hours after the onset of chest pain. Gas chromatography–mass spectrometry and liquid chromatography–mass spectrometry were applied to identify and quantify the plasma metabolites.
Results revealed that metabolites belonging to pyrimidine, methionine, and arginine metabolism were elevated in MI plasma samples. Specifically, deoxyuridine (dU), homoserine, and methionine were identified as potential markers for distinguishing MI cases from other cardiac chest pain cases after the onset of chest pains. Individuals with high plasma abundance of dU, homoserine, or methionine were also found to have increased risk of MI.
"We analyzed circulating metabolites in blood plasma samples from cardiac chest pain patients, including heart attack cases and other cardiac chest pain cases, to identify potential markers for heart attack diagnosis and early warning," said contributing author Dr. Xiangqing Kong, a senior researcher at Nanjing Medical University. "Such markers could be helpful in confirming heart attack in a timely manner when angiography is unavailable."
The identification of metabolites useful for early diagnosis of MI was described in the April 23, 2021, online edition of the journal Frontiers in Cardiovascular Medicine.
Related Links:
Nanjing Medical University
Investigators at Nanjing Medical University (People’s Republic of China) were working to develop a simple blood test to aid clinicians in diagnosing a heart attack with a rapid, noninvasive assay method.
To this end, they analyzed plasma metabolites in MI and non-MI chest pain cases to identify markers for diagnosis of MI based on metabolomics. Non-MI cardiac chest pain cases included unstable angina (UA), myocarditis, and valvular heart diseases. A total of 230 volunteers were recruited, consisting of 146 chest pain patients admitted with suspected MI (85 MIs and 61 non-MI chest pain cases) and 84 control individuals. Blood samples from all suspected MI cases were collected not longer than six hours after the onset of chest pain. Gas chromatography–mass spectrometry and liquid chromatography–mass spectrometry were applied to identify and quantify the plasma metabolites.
Results revealed that metabolites belonging to pyrimidine, methionine, and arginine metabolism were elevated in MI plasma samples. Specifically, deoxyuridine (dU), homoserine, and methionine were identified as potential markers for distinguishing MI cases from other cardiac chest pain cases after the onset of chest pains. Individuals with high plasma abundance of dU, homoserine, or methionine were also found to have increased risk of MI.
"We analyzed circulating metabolites in blood plasma samples from cardiac chest pain patients, including heart attack cases and other cardiac chest pain cases, to identify potential markers for heart attack diagnosis and early warning," said contributing author Dr. Xiangqing Kong, a senior researcher at Nanjing Medical University. "Such markers could be helpful in confirming heart attack in a timely manner when angiography is unavailable."
The identification of metabolites useful for early diagnosis of MI was described in the April 23, 2021, online edition of the journal Frontiers in Cardiovascular Medicine.
Related Links:
Nanjing Medical University
Latest Molecular Diagnostics News
- New Respiratory Panel Expands Pathogen Detection to 25 Targets
- Simple Nasal Swab May Reveal Early Signs of Alzheimer’s Disease
- Blood Biomarker Predicts Cognitive Outcomes After Cardiac Arrest
- Liquid Biopsy Enables Faster Diagnosis of Childhood Cancer in Africa
- Blood Test Helps Guide Treatment in Older Women with Breast Cancer
- Rapid Host-Response Test Distinguishes Bacterial and Viral Infections in Minutes
- Liquid Biopsy Method Pinpoints Disease Source From a Single Drop of Blood
- Study Reveals Widespread Errors in Gene Variant Naming
- New Blood Test Aims to Transform Liver Cancer Surveillance
- New Biomarkers Indicate Higher Liver Cancer Risk in Chronic Hepatitis B Patients
- Precision Analyzer Reveals ‘Chameleon Proteins’ Causing Intractable Diseases
- Alzheimer's Blood Marker Could Improve Detection of Heart and Kidney Diseases
- Single Blood Test Predicts Heart Diseases 15 Years Before Onset
- Blood Immune 'Fingerprint' Predicts Side Effects of New Alzheimer's Drug
- Clinical Diagnostic Test Detects Additional Genetic Variants in Acute Leukemia Patients
- Blood Test Predicts Dementia in Women 25 Years Before Symptoms Begin
Channels
Clinical Chemistry
view channel
CSF Biomarker Improves Diagnosis of Parkinson’s Disease and Lewy Body Dementia
Parkinson’s disease and dementia with Lewy bodies are frequently misdiagnosed, often being confused with Alzheimer’s disease because of overlapping symptoms. Objective diagnostics for these synucleinopathies... Read more
Simple Urine Home Test Kit Could Detect Early-Stage Breast Cancer
Breast cancer is the most commonly diagnosed cancer among women globally and remains a leading cause of cancer-related deaths in more than 100 countries. Current diagnostic pathways rely on mammography,... Read moreHematology
view channel
Rapid Cartridge-Based Test Aims to Expand Access to Hemoglobin Disorder Diagnosis
Sickle cell disease and beta thalassemia are hemoglobin disorders that often require referral to specialized laboratories for definitive diagnosis, delaying results for patients and clinicians.... Read more
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read moreImmunology
view channel
Study Identifies Inflammatory Pathway Driving Immunotherapy Resistance in Bladder Cancer
Bladder cancer remains a prevalent malignancy with variable responses to immune checkpoint inhibitors. Clinicians often observe elevated C-reactive protein and interleukin-6 in affected patients, yet the... Read more
Microfluidic Chip Detects Cancer Recurrence from Immune Response Signals
Early identification of treatment response and relapse remains a major challenge in solid tumors, where minimal residual disease is difficult to detect with routine imaging and blood tests.... Read moreMicrobiology
view channel
Breath Analysis Approach Offers Rapid Detection of Bacterial Infection
Accurate and rapid identification of bacterial infections remains challenging in acute care, where delays can hinder timely, targeted therapy. Infectious diseases are a major cause of mortality worldwide,... Read more
Study Highlights Accuracy Gaps in Consumer Gut Microbiome Kits
Direct-to-consumer gut microbiome kits promise personalized insights by profiling fecal bacteria and generating health readouts, but their analytical accuracy remains uncertain. A new study shows that... Read more
WHO Recommends Near POC Tests, Tongue Swabs and Sputum Pooling for TB Diagnosis
Tuberculosis (TB) remains one of the world’s leading infectious disease killers, yet millions of cases go undiagnosed or are detected too late. Barriers such as reliance on sputum samples, limited laboratory... Read morePathology
view channel
Biopsy-Based Gene Test Predicts Recurrence Risk in Lung Adenocarcinoma
Lung cancer is the leading cause of cancer death, killing more people in the United States than breast, prostate, and colon cancers combined. In lung adenocarcinoma (LUAD), tumors that invade nearby blood... Read more
AI-Powered Tool to Transform Dermatopathology Workflow
Skin cancer accounts for the largest number of cancer diagnoses in the United States, placing sustained pressure on pathology services. Diagnostic interpretation can be variable for challenging melanocytic... Read moreTechnology
view channel
Portable Breath Sensor Detects Pneumonia Biomarkers in Minutes
Pneumonia is commonly confirmed with chest X-rays or laboratory assays that can take hours, delaying clinical decisions in acute and outpatient settings. Breath-based diagnostics promise faster answers... Read more
New Electronic Pipette Enhances Workflows with Touchscreen Control
Manual pipetting remains a routine yet error-prone step that can affect reproducibility and throughput in clinical and research laboratories. Training demands and ergonomic strain also add variability... Read more
AI Model Outperforms Clinicians in Rare Disease Detection
Rare diseases affect an estimated 300 million people worldwide, yet diagnosis is often protracted and error-prone. Many conditions present with heterogeneous signs that overlap with common disorders, leading... Read more
AI-Driven Diagnostic Demonstrates High Accuracy in Detecting Periprosthetic Joint Infection
Periprosthetic joint infection (PJI) is a rare but serious complication affecting 1% to 2% of primary joint replacement surgeries. The condition occurs when bacteria or fungi infect tissues around an implanted... Read moreIndustry
view channel
Integrated DNA Technologies Expands into Clinical Diagnostics
Integrated DNA Technologies (IDT; Coralville, Iowa, USA) has announced the launch of Archer FUSIONPlex-HT Dx and VARIANTPlex-HT Dx. This launch marks the company’s first in vitro diagnostic (IVD) offerings... Read more








